Theoretical Investigation of the Cooperation of Iminoguanidine with the Enzymes-Binding Domain of Covid-19 and Bacterial Lysozyme Inhibitors and their Pharmacokinetic Properties

Emmanuel Israel Edache\textsuperscript{1,2*}, Adamu Uzairu\textsuperscript{2}, Paul Andrew Mamza\textsuperscript{2}, Gideon Adamu Shallangwa\textsuperscript{2}

\textsuperscript{1}Department of Pure and Applied Chemistry, University of Maiduguri, Borno State, Nigeria.
\textsuperscript{2}Department of Chemistry, Ahmadu Bello University, Zaria, Nigeria.

*Corresponding author: Emmanuel Israel Edache, email: edacheson2004@gmail.com

Received January 24\textsuperscript{th}, 2022; Accepted August 1\textsuperscript{st}, 2022.

DOI for the article: \url{http://dx.doi.org/10.29356/jmcs.v66i4.1726}
Fig. S1. The connection between the observed and predicted activities by GA-MLR.

Fig. S2. Residuals of iminoguanidine derivatives against the experimental values of pIC50 using GA-MLR model.
Fig. S3. Plot of Y-randomization test: All gotten values for R² and Q² test are approximately 0.11 and – 0.31, respectively.

Fig. S4. William plot for the developed 2D-QSAR model.
Fig. S5. Insubria plot for the 2D-QSAR model, using the two descriptors.
**Fig. S6.** 2D interaction contour map with the key protein residues after MD simulation.
Fig. S7. MDs simulations study of modeled SARS-CoV-2 and compound 15 (A) Total energy, (B) Kinetic energy, and (C) Potential energy.